Clinical Trials Browser

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT03294694 2025-05-31

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1 Terminated

33 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms

NCT02974725 2025-04-13

A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

Phase 1 Terminated

241 enrolled

DermatologicThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma

NCT05384119 2025-02-21

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Phase 1 Terminated

6 enrolled

Breast

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast

Breast Neoplasms

NCT04657679 2024-11-26

LEANORA

Phase 4 Terminated

21 enrolled 19 charts

Breast

Breast Neoplasms

NCT04801966 2023-05-10

TAILOR

Phase NA Terminated

3 enrolled

Tumor-Agnostic

Neoplasms

NCT02734615 2022-08-01

Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers

Phase 1 Terminated

199 enrolled

Breast

Advanced or Metastatic ER+ Breast Cancer

NCT02414724 2022-07-25

Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma

Phase 1 Terminated

10 enrolled

Lymphoid

Lymphoma

NCT03905343 2021-06-16

Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC

Phase 3 Terminated

25 enrolled

Breast

Breast Neoplasms

NCT02524119 2021-02-01

LEE001

Phase 2 Terminated

5 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02703571 2020-12-21

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Phase 1 Terminated

95 enrolled

Gastrointestinal

Pancreatic Neoplasms, Colorectal Neoplasms

NCT02607124 2020-11-05

A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy

Phase 1/2 Terminated

11 enrolled 10 charts

CNS

Diffuse Intrinsic Pontine Glioma, Glioma

NCT03050398 2020-05-28

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Phase 3 Terminated

8 enrolled 4 charts

BreastEndocrine

Breast Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02429089 2020-01-09

CETLEE011

Phase 1 Terminated

21 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Neoplasm Metastasis, Recurrence

NCT01747876 2019-11-22

Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma

Phase 1 Terminated

32 enrolled 14 charts

CNS

Neuroblastoma

NCT03179956 2019-02-25

Impact of Ribociclib on Head and Neck Squamous Cell Cancer

Phase EARLY_PHASE1 Terminated

1 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01777776 2016-09-13

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Phase 1/2 Terminated

28 enrolled 14 charts

Dermatologic

Melanoma

NCT01919229 2016-01-01

MONALEESA-1

Phase 2 Terminated

14 enrolled 7 charts

Breast

Breast Neoplasms